A common antifungal drug now has a faster, cheaper test for patient levels

US health regulators have made it easier to get approval for tests that measure levels of the antifungal drug voriconazole in patients. This means doctors will have more options to quickly check if patients are getting the right dose, which can prevent serious side effects or treatment failure.

For years, doctors had limited ways to precisely measure how much voriconazole was in a patient's system. This drug is tricky because too little means the infection doesn't clear, and too much can cause liver damage or hallucinations. By simplifying the approval process for these tests, the FDA is making it easier for new, potentially faster or cheaper, tests to reach the market. This helps doctors tailor treatment more effectively for each patient.